SCHEMBL2187165

SCHEMBL2187165

CC(C)([C@@H]1CCN(c2ncc(C(F)(F)F)cc2S(C)(=O)=O)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 11/20 0.50
NR1I2 O75469 4/20 0.50
CYP3A4 P08684 3/20 0.50
ALDH1A1 P00352 2/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
DRD2 P14416 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
HSD11B1 P28845 1/20 0.38
KDM2B Q8NHM5 1/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
NR1H2 P55055 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2189829 1.00 CACNA1B (0.50) CACNA1BNR1I2CYP3A4ALDH1A1USP2
SCHEMBL2190979 0.94 CACNA1B (0.46) CACNA1BNR1I2CYP3A4PTGS1PTGS2
SCHEMBL2190029 0.94 CACNA1B (0.46) CACNA1BNR1I2CYP3A4PTGS1PTGS2
SCHEMBL2189941 0.91 CACNA1B (0.45) CACNA1BNR1I2CYP3A4ALDH1A1USP2
SCHEMBL2188764 0.91 CACNA1B (0.45) CACNA1BNR1I2CYP3A4ALDH1A1USP2
SCHEMBL12415664 0.91 CACNA1B (0.45) CACNA1BNR1I2CYP3A4ALDH1A1USP2
SCHEMBL1728213 0.90 CYP3A4 (0.47) CACNA1BNR1I2CYP3A4ALDH1A1USP2
SCHEMBL2190611 0.90 CYP3A4 (0.47) CACNA1BNR1I2CYP3A4ALDH1A1USP2
SCHEMBL1710957 0.90 CYP3A4 (0.47) CACNA1BNR1I2CYP3A4ALDH1A1USP2
SCHEMBL2190814 0.89 ALDH1A1 (0.47) CACNA1BNR1I2CYP3A4ALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CACNA1B 23/4885NR1I2 765/4885CYP3A4 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.